title: Rhabdomyolysis secondary to quetiapine.
abstract: Quetiapine is one of the drugs used most in current Psychiatry due to its therapeutic efficiency and clinical safety. We report the case of a 26-year-old male patient with severe mental retardation due to Y-chromosome partial deletion who initiated treatment with quetiapine for the control of his aggressiveness, and who developed severe rhabdomyolysis two weeks later. In spite of the confirmed clinical safety of quetiapine, doctors must monitor the appearance of rare but serious adverse effects as that presented in this clinical case.
authors.affiliation: Hospital Santiago Apóstol, Servicio de Medicina Interna, Vitoria-Gasteiz, España. javier_velasco_montes@hotmail.com
authors.forename: Javier
authors.initials: J
authors.lastname: Velasco-Montes
authors.forename: Itziar
authors.initials: I
authors.lastname: Oriñuela-González
authors.forename: Ainhoa Z
authors.initials: AZ
authors.lastname: Sanjuán-López
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D003987:Dibenzothiazepines / Q000009:adverse effects*; D006801:Humans; D008297:Male; D000069348:Quetiapine Fumarate; D012206:Rhabdomyolysis / Q000139:chemically induced*
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate